NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Basilea Pharmaceutica AG (SW: BSLN)

 
BSLN Technical Analysis
2
As on 17th Jan 2025 BSLN STOCK Price closed @ 40.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 39.27 & Strong Sell for SHORT-TERM with Stoploss of 44.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BSLNSTOCK Price

Open 41.20 Change Price %
High 41.60 1 Day -1.20 -2.89
Low 40.25 1 Week -2.85 -6.60
Close 40.30 1 Month -1.10 -2.66
Volume 29486 1 Year -3.55 -8.10
52 Week High 48.65 | 52 Week Low 32.25
 
SW Switzerland Most Active Stocks
CSGN 0.82 0.00%
CSGN 0.82 0.00%
UBSG 31.13 2.91%
UBSG 31.13 2.91%
NESN 74.20 0.41%
NESN 74.20 0.41%
NOVN 89.32 -1.40%
NOVN 89.32 -1.40%
ABBN 50.70 2.09%
ABBN 50.70 2.09%
 
SW Switzerland Top Gainers Stocks
PRFN 0.03 50.00%
PRFN 0.03 50.00%
CADN 0.03 50.00%
BLS 0.13 18.18%
BLS 0.13 18.18%
BLS 0.13 18.18%
NEWN 0.94 17.50%
HLEE 8.45 16.55%
MBTN 2.70 11.57%
CASN 1.90 8.57%
 
SW Switzerland Top Losers Stocks
STLN 3.85 -15.38%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
EVE 1.08 -8.47%
 
 
BSLN
Daily Charts
BSLN
Intraday Charts
Whats New @
Bazaartrend
BSLN
Free Analysis
 
BSLN Important Levels Intraday
RESISTANCE42.90
RESISTANCE42.07
RESISTANCE41.55
RESISTANCE41.04
SUPPORT39.56
SUPPORT39.05
SUPPORT38.53
SUPPORT37.70
 
BSLN Forecast January 2025
4th UP Forecast57.26
3rd UP Forecast51.82
2nd UP Forecast48.46
1st UP Forecast45.1
1st DOWN Forecast35.5
2nd DOWN Forecast32.14
3rd DOWN Forecast28.78
4th DOWN Forecast23.34
 
BSLN Weekly Forecast
4th UP Forecast46.95
3rd UP Forecast44.82
2nd UP Forecast43.50
1st UP Forecast42.18
1st DOWN Forecast38.42
2nd DOWN Forecast37.10
3rd DOWN Forecast35.78
4th DOWN Forecast33.65
 
BSLN Forecast2025
4th UP Forecast73.06
3rd UP Forecast62.55
2nd UP Forecast56.06
1st UP Forecast49.57
1st DOWN Forecast31.04
2nd DOWN Forecast24.54
3rd DOWN Forecast18.05
4th DOWN Forecast7.54
 
 
BSLN Other Details
Segment EQ
Market Capital 500739264.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BSLN Address
BSLN
 
BSLN Latest News
 
Your Comments and Response on Basilea Pharmaceutica AG
 
BSLN Business Profile
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia in European and various non-European countries. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. The company was founded in 2000 and is headquartered in Basel, Switzerland. Address: Grenzacherstrasse 487, Basel, Switzerland, 4058
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service